Back to Results

Pilot Study to Evaluate Safety and Tolerability of Inhaled N-Acetylcysteine in Pulmonary Fibrosis

Study category: Respiratory

Is this Study for You?

Let's Get Started!


This study plans to learn more about the safety and tolerability of inhaled N-Acetylcysteine (NAC) in patients with pulmonary fibrosis. We will also create a bank of data, blood, and sputum from IPF patients for future research. NAC is a medication used to loosen thick mucus. NAC was initially licensed for use in 1968. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system, and it is available as a generic medication and is not very expensive. Inhaled NAC has been used as a mucus-dissolving therapy in respiratory conditions with excessive and/or thick mucus production.




Diagnosed with IPF


Feasibility - Exploratory studies, involving very limited human exposure, with no therapeutic or diagnostic intent.

Type of Study



Outpatient CTRC
University of Colorado Hospital

Principal Investigator
Mark Steele,  MD

Mark Steele, MD

Study ID

Protocol Number: 17-1477


Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers